Longitude Capital
  • ABOUT
  • TEAM
  • PORTFOLIO
  • NEWS
  • CONTACT
  • LP LOGIN
Select Page

Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update

by Seini Moimoi | May 16, 2022 | Uncategorized, Portfolio News

89bio Initiates Phase 2b ENLIVEN Trial of BIO89-100 for the Treatment of NASH

by Seini Moimoi | Jun 10, 2021 | Uncategorized

Inozyme Announces Acceptance of First European Clinical Trial Application for Phase 1/2 Clinical Trial of INZ-701 in ABCC6 Deficiency

by Seini Moimoi | Jun 9, 2021 | Uncategorized

Nabriva Therapeutics and Sinovant Sciences Restructure License Agreement for XENLETA for Community-Acquired Bacterial Pneumonia in China

by Seini Moimoi | Dec 7, 2020 | Uncategorized

Sierra Oncology Strengthens Management Team to Implement North American Pre-Commercialization Strategy for Momelotinib

by Seini Moimoi | Aug 6, 2020 | Uncategorized

Tricida Announces First Quarter 2020 Financial Results

by Seini Moimoi | May 7, 2020 | Uncategorized

« Older Entries

Media Contact

Maggie Jamison

mjamison@longitudecapital.com

650-854-5700

  • Facebook
  • Twitter
  • Google
  • RSS
footer-logo

LP Login

© 2023 Longitude Capital. All rights reserved.
  • Privacy Policy
  • Disclaimer